Profile data is unavailable for this security.
About the company
Instil Bio, Inc. is a clinical-stage biopharmaceutical company focused on developing a pipeline of novel therapies. The Company seeks to in-license/acquire and develop novel therapeutic candidates in diseases with significant unmet medical need. The Company’s subsidiary, Axion Bio, Inc., in-licensed certain bispecific antibodies, including AXN-2510/IMM2510 and AXN-27M/IMM27M, a monoclonal antibody targeting cytotoxic T-lymphocyte associated antigen 4, or CTLA-4. AXN-2510/IMM2510, the lead in-licensed product candidate, is a novel and differentiated PD-L1xVEGF bispecific antibody in development for the treatment of multiple solid tumor cancers. AXN-27M/IMM27M is an antibody-dependent cellular cytotoxicity-enhanced monoclonal antibody targeting CTLA-4, which has been designed to promote intratumoral regulatory T cell depletion to enhance the efficacy and reduce the toxicity associated with first-generation anti-CTLA-4 antibodies.
- Revenue in USD (TTM)0.00
- Net income in USD-75.08m
- Incorporated2018
- Employees14.00
- LocationInstil Bio Inc3963 Maple Avenue, Suite 350DALLAS 75219United StatesUSA
- Phone+1 (972) 499-3350
- Fax+1 (302) 531-3150
- Websitehttps://instilbio.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| NRX Pharmaceuticals Inc | 242.00k | -38.06m | 50.58m | 2.00 | -- | -- | -- | 208.99 | -2.32 | -2.32 | 0.0141 | -0.9304 | 0.0249 | -- | -- | -- | -391.21 | -210.73 | -- | -603.16 | 59.92 | -- | -15,727.69 | -- | -- | -- | -- | -- | -- | -- | 16.69 | -- | -- | -- |
| Plus Therapeutics Inc (USA) | 5.26m | -20.58m | 50.72m | 21.00 | -- | 7.17 | -- | 9.65 | -1.71 | -1.71 | 0.062 | 0.0384 | 0.41 | -- | -- | 250,381.00 | -160.45 | -80.94 | -- | -211.40 | -- | -- | -391.33 | -605.55 | -- | -2.19 | 0.00 | -- | 18.54 | -3.61 | 2.54 | -- | 59.47 | -- |
| Acrivon Therapeutics Inc | 0.00 | -81.75m | 51.43m | 75.00 | -- | 0.3999 | -- | -- | -2.13 | -2.13 | 0.00 | 4.08 | 0.00 | -- | -- | 0.00 | -45.42 | -- | -49.51 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -33.40 | -- | -- | -- |
| Mink Therapeutics Inc | 0.00 | -12.36m | 51.82m | 23.00 | -- | -- | -- | -- | -3.03 | -3.03 | 0.00 | -2.94 | 0.00 | -- | -- | 0.00 | -110.62 | -144.86 | -1,640.97 | -870.32 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 51.98 | -- | -- | -- |
| Tscan Therapeutics Inc | 8.42m | -142.60m | 52.89m | 146.00 | -- | 0.3672 | -- | 6.28 | -1.12 | -1.12 | 0.066 | 2.54 | 0.0276 | -- | -- | 43,417.53 | -46.73 | -38.91 | -51.63 | -43.93 | -- | -- | -1,692.96 | -735.59 | -- | -- | 0.1837 | -- | -86.62 | -- | -42.91 | -- | 25.13 | -- |
| Estrella Immunopharma Inc | 0.00 | -13.50m | 53.17m | -- | -- | -- | -- | -- | -0.3697 | -0.3697 | 0.00 | -0.2605 | 0.00 | -- | -- | -- | -371.99 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| Beyondspring Inc | 0.00 | -7.83m | 53.24m | 40.00 | -- | -- | -- | -- | -0.1942 | -0.0148 | 0.00 | -0.788 | -- | -- | -- | 0.00 | -- | -61.84 | -- | -81.30 | -- | -- | -- | -6,633.90 | -- | -- | -- | -- | -- | -- | 35.26 | -- | 123.69 | -- |
| Kazia Therapeutics Ltd (ADR) | 80.63k | -14.64m | 53.77m | 12.00 | -- | -- | -- | 666.84 | -12.28 | -12.28 | 0.0562 | -3.63 | 0.0083 | -- | 0.0571 | -- | -149.76 | -64.49 | -- | -99.77 | -- | -- | -18,159.65 | -573.31 | -- | -- | -- | -- | -95.09 | 11.58 | 22.69 | -- | -- | -- |
| Instil Bio Inc | 0.00 | -75.08m | 54.19m | 14.00 | -- | 0.45 | -- | -- | -11.39 | -11.39 | 0.00 | 17.76 | 0.00 | -- | -- | 0.00 | -31.00 | -34.59 | -32.06 | -36.59 | -- | -- | -- | -469,515.20 | -- | -19.23 | 0.4127 | -- | -- | -- | 52.50 | -- | 116.55 | -- |
| Metagenomi Therapeutics Inc | 30.91m | -88.74m | 54.80m | 124.00 | -- | 0.3072 | -- | 1.77 | -2.39 | -2.39 | 0.8308 | 4.75 | 0.102 | -- | 39.91 | 153,034.70 | -29.27 | -- | -33.42 | -- | -- | -- | -287.06 | -- | -- | -- | 0.00 | -- | 16.84 | -- | -14.36 | -- | -- | -- |
| Grace Therapeutics, Inc | 0.00 | -5.98m | 55.86m | 32.00 | -- | 0.8608 | -- | -- | -0.3607 | -0.3607 | 0.00 | 4.19 | 0.00 | -- | -- | -- | -9.22 | -24.13 | -9.46 | -25.07 | -- | -- | -- | -48,136.22 | -- | -- | 0.00 | -- | -- | -- | 25.56 | -- | -- | -- |
| Tevogen Bio Holdings Inc | 0.00 | -31.42m | 56.40m | 18.00 | -- | -- | -- | -- | -0.2138 | -0.2138 | 0.00 | -0.0396 | 0.00 | -- | -- | 0.00 | -706.86 | -- | -- | -- | -- | -- | -- | -- | -- | -231.10 | -- | -- | -- | -- | 83.01 | -- | -- | -- |
| PMV Pharmaceuticals Inc | 0.00 | -82.71m | 59.06m | 63.00 | -- | 0.4861 | -- | -- | -1.58 | -1.58 | 0.00 | 2.28 | 0.00 | -- | -- | 0.00 | -46.29 | -21.46 | -49.90 | -22.32 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 14.87 | -- | 43.14 | -- |
| RetinalGenix Technologies Inc | 0.00 | -2.67m | 59.54m | 0.00 | -- | -- | -- | -- | -0.1455 | -0.1455 | 0.00 | -0.1168 | 0.00 | -- | -- | -- | -5,576.42 | -14,417.91 | -- | -- | -- | -- | -- | -- | -- | -684.26 | -- | -- | -- | -- | -106.65 | -- | -- | -- |
Data as of Feb 13 2026. Currency figures normalised to Instil Bio Inc's reporting currency: US Dollar USD
26.37%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| BML Capital Management LLCas of 31 Dec 2025 | 645.60k | 9.52% |
| CPMG, Inc.as of 30 Sep 2025 | 410.92k | 6.06% |
| Millennium Management LLCas of 30 Sep 2025 | 196.74k | 2.90% |
| The Vanguard Group, Inc.as of 31 Dec 2025 | 166.97k | 2.46% |
| Morgan Stanley & Co. LLCas of 31 Dec 2025 | 83.99k | 1.24% |
| Renaissance Technologies LLCas of 31 Dec 2025 | 67.80k | 1.00% |
| Boxer Capital Management LLCas of 30 Sep 2025 | 60.70k | 0.90% |
| Dimensional Fund Advisors LPas of 31 Dec 2025 | 55.01k | 0.81% |
| BlackRock Fund Advisorsas of 31 Dec 2025 | 50.49k | 0.74% |
| Nomura Investment Management Business Trustas of 30 Sep 2025 | 50.00k | 0.74% |
More ▼
Data from 30 Sep 2025 - 31 Dec 2025Source: FactSet Research Systems Inc.
